Europe Rare Neurological Disease Treatment Market to Grow at a CAGR of 8.1% to reach US$ 3,763.41 Million from 2019 to 2027

Europe Rare Neurological Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Other Indication); Drug Type (Organic Compounds, Biologics); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies); Mode of Administration (Oral, Injectables) and Country

Publication Month: Apr 2020 | Report Code: TIPRE00010244 | No. of Pages: 154 | Category: Pharmaceuticals | Status: Published
Covid

The Europe rare neurological disease treatment market is expected to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019. The market is estimated to grow with a CAGR of 8.1% from 2019-2027.

 

The growth of the market is driven by factors such as the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the Europe region. However, higher cost of rare neurological disease treatments is likely to restrain the market growth to a certain extent.

 

A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.

 

In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. According to a data published by World Health Organization (WHO), it is estimated that about 30 million Europeans in 27 EU-countries suffer from a rare disease. Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.

 

Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization are taking constructive steps to encourage the research activities to find a remedy for rare neurological disease treatment. For instance, in recent decades, considerable attention has been paid worldwide to stimulate the research, development and marketing of medicinal products for rare diseases. In the EU over 70 products have been approved as therapy in more than 45 rare diseases indications. An analysis of designated and approved orphan medicines in the EU revealed that treatment of rare diseases was mainly developed in the field of oncology followed by metabolism. Such increasing awareness and developments for rare neurological diseases are likely to boost the growth of the rare neurological disease treatment market in Europe during the forecast period.

 

The increasing use of rare neurological disease treatment in medical treatment cases in Europe is expected to drive rare neurological disease treatment market the growing pharmaceuticals industry in the country create a lucrative opportunity and the presence of an established market for rare neurological disease treatment.

 

Rest of Europe Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)

Rest of Europe Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)

Get more information on this report :


EUROPE RARE NEUROLOGICAL DISEASE TREATMENT – MARKET SEGMENTATION

Europe Rare Neurological Disease Treatment Market - By Indication

  • Narcolepsy
  • Amyotrophic Lateral Sclerosis
  • Alzheimer’s Disease
  • Multiple Sclerosis
  • Spinal Muscular Atrophy (SMA)
  • Duchenne Muscular Dystrophy
  • Other Indications

Europe Rare Neurological Disease Treatment Market - By Drug Type

  • Organic Compounds
  • Biologics

Europe Rare Neurological Disease Treatment Market - By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Europe Rare Neurological Disease Treatment Market - By Mode of Administration

  • Oral
  • Injectable

Europe Rare Neurological Disease Treatment Market - By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain

Europe Rare Neurological Disease Treatment Market - Companies Mentioned

  • Allergan plc.
  • Bayer AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Rare Neurological Disease Treatment Market – By Indication

1.3.2        Europe Rare Neurological Disease Treatment Market – By Drug Type

1.3.3        Europe Rare Neurological Disease Treatment Market – By Distribution Channel

1.3.4        Europe Rare Neurological Disease Treatment Market – By Mode of Administration

1.3.5        Europe Rare Neurological Disease Treatment Market – By Country

2.           Europe Rare Neurological Disease Treatment Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Europe Rare Neurological Disease Treatment Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Rare Neurological Disease Treatment Market - Europe PEST Analysis

4.3         Expert Opinion

5.           Europe Rare Neurological Disease Treatment Market - Key Market Dynamics

5.1         Key Market Drivers

5.1.1        Rising Prevalence of Rare Neurological Diseases

5.1.2        Favourable Pipeline Drugs and Robust Research Activities for the Treatment of Rare Neurological Diseases

5.2         Key Restraints

5.2.1        High Treatment Cost for Rare Neurological Diseases

5.3         Key Market Opportunities

5.3.1        Increasing Awareness of Rare Neurological Diseases Coupled with Developing Healthcare Infrastructure

5.4         Future Trend

5.4.1        Artificial Intelligence for the Treatment of Rare Neurological Diseases

5.5         Impact Analysis

6.           Rare Neurological Disease Treatment Market – Europe Analysis

6.1         Europe Rare Neurological Disease Treatment Market Revenue Forecasts and Analysis

7.           Europe Rare Neurological Disease Treatment Market Analysis And Forecasts To 2027 – By Indication

7.1         Overview

7.2         Europe Rare Neurological Disease Treatment Market, By Indication 2019 & 2027 (%)

7.2.1        Europe Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Indication (US$ Mn)

7.3         Narcolepsy

7.3.1        Overview

7.3.2        Europe Narcolepsy Market Revenue and Forecast to 2027 (US$ Mn)

7.4         Amyotrophic Lateral Sclerosis

7.4.1        Overview

7.4.2        Europe Amyotrophic Lateral Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)

7.5         Alzheimer’s Disease

7.5.1        Overview

7.5.2        Europe Alzheimer’s Disease Market Revenue and Forecast to 2027 (US$ Mn)

7.6         Multiple Sclerosis

7.6.1        Overview

7.6.2        Europe Multiple Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)

7.7         Spinal Muscular Atrophy (SMA)

7.7.1        Overview

7.7.2        Europe Spinal Muscular Atrophy Market Revenue and Forecast to 2027 (US$ Mn)

7.8         Duchenne Muscular Dystrophy

7.8.1        Overview

7.8.2        Europe Duchenne Muscular Dystrophy Market Revenue and Forecast to 2027 (US$ Mn)

7.9         Other Indications

7.9.1        Overview

7.9.2        Europe Other Indications Market Revenue and Forecast to 2027 (US$ Mn)

8.           Europe Rare Neurological Disease Treatment Market Analysis– By Drug Type

8.1         Overview

8.2         Europe Rare Neurological Disease Treatment Market, By Drug Type 2019-2027 (%)

8.2.1        Europe Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Drug Type (US$ Mn)

8.3         Organic Compounds

8.3.1        Overview

8.3.2        Europe Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)

8.4         Biologics

8.4.1        Overview

8.4.2        Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

9.           Europe Rare Neurological Disease Treatment Market Analysis– By Distribution Channel

9.1         Overview

9.2         Europe Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)

9.2.1        Europe Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

9.3         Online Pharmacies

9.3.1        Overview

9.3.2        Europe Online Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)

9.4         Hospital Pharmacies

9.4.1        Overview

9.4.2        Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

9.5         Retail Pharmacies

9.5.1        Overview

9.5.2        Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.        Europe Rare Neurological Disease Treatment Market Analysis– By Mode of Administration

10.1      Overview

10.2      Europe Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)

10.2.1     Europe Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Mode of Administration (US$ Mn)

10.3      Oral

10.3.1     Overview

10.3.2     Europe Oral Market Revenue and Forecast to 2027 (US$ Mn)

10.4      Injectable

10.4.1     Overview

10.4.2     Europe Injectable Market Revenue and Forecasts to 2027 (US$ Mn)

11.        Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1      Europe Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027

11.1.1     Overview

11.1.2     Europe: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (USD Million)

11.1.3     Europe: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.4     Europe: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.5     Europe: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.6     Europe: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.7     Europe: Rare Neurological Disease Treatment Market, by Country, 2019& 2027 (%)

11.1.8     Germany: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1       Germany: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2       Germany: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.8.3       Germany: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.8.4       Germany: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.8.5       Germany: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.9     United Kingdom: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1       United Kingdom: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2       United Kingdom: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.9.3       United Kingdom: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.9.4       United Kingdom: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.9.5       United Kingdom: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.10  France: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1    France: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2    France: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.10.3    France: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.10.4    France: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.10.5    France: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.11  Spain: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.1    Spain: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.2    Spain: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.11.3    Spain: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.11.4    Spain: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.11.5    Spain: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.12  Italy: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.1    Italy: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.2    Italy: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)

11.1.12.3    Italy: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)

11.1.12.4    Italy: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)

11.1.12.5    Italy: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)

12.        Impact Of COVID-19 Pandemic On Europe Rare Neurological Diseases Treatment Market

12.1      Europe: Impact assessment of COVID-19 Pandemic

13.        Europe Rare Neurological Disease Treatment Market Industry Landscape

13.1      Overview

13.2      Organic Growth Strategies

13.2.1     Overview

14.        Company Profiles

14.1      Allergan Plc.

14.1.1     Key Facts

14.1.2     Business Description

14.1.3     Products and Services

14.1.4     Financial Overview

14.1.5     SWOT Analysis

14.1.6     Key Developments

14.2      Bayer AG

14.2.1     Key Facts

14.2.2     Business Description

14.2.3     Products and Services

14.2.4     Financial Overview

14.2.5     SWOT Analysis

14.2.6     Key Developments

14.3      GlaxoSmithKline plc.

14.3.1     Key Facts

14.3.2     Business Description

14.3.3     Products and Services

14.3.4     Financial Overview

14.3.5     SWOT Analysis

14.3.6     Key Developments

14.4      Novartis AG

14.4.1     Key Facts

14.4.2     Business Description

14.4.3     Products and Services

14.4.4     Financial Overview

14.4.5     SWOT Analysis

14.4.6     Key Developments

14.5      Sanofi

14.5.1     Key Facts

14.5.2     Business Description

14.5.3     Products and Services

14.5.4     Financial Overview

14.5.5     SWOT Analysis

14.5.6     Key Developments

15.        Appendix

15.1      About The Insight Partners

15.2      Glossary of Terms

 

LIST OF TABLES

Table 1.             Europe Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Indication (US$ Mn)

Table 2.             Europe Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Drug Type (US$ Mn)

Table 3.             Europe Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

Table 4.             Europe Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Mode of Administration (US$ Mn)

Table 5.             Europe Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 6.             Europe Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 7.             Europe Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)

Table 8.             Europe Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 9.             Germany Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 10.          Germany Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 11.          Germany Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12.          Germany Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13.          United Kingdom Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 14.          United Kingdom Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 15.          United Kingdom Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027  (USD Million)

Table 16.          United Kingdom Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 17.          France Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027  (USD Million)

Table 18.          France Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 19.          France Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20.          France Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 21.          Spain Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 22.          Spain Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 23.          Spain Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)

Table 24.          Spain Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 25.          Italy Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 26.          Italy Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)

Table 27.          Italy Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)

Table 28.          Italy Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 29.          Recent Inorganic Growth Strategies In The Rare Neurological Disease Treatment Market

Table 30.          Recent Organic Growth Strategies In The Rare Neurological Disease Treatment Market

Table 31.          Glossary of Terms, Rare Neurological Disease Treatment Market

 

LIST OF FIGURES

Figure 1.           Rare Neurological Disease Treatment Market Segmentation

Figure 2.           Europe Rare Neurological Disease Treatment Market Overview

Figure 3.           Alzheimer’s Disease Segment Held Largest Share of Indication Segment in Rare Neurological Disease Treatment Market

Figure 4.           Germany Is Expected To Show Remarkable Growth During The Forecast Period

Figure 5.           Europe Rare Neurological Disease Treatment Market- Leading Country Markets (US$ Mn)

Figure 6.           Rare Neurological Disease Treatment Market, Industry Landscape

Figure 7.           Rare Neurological Disease Treatment Market - Europe PEST Analysis

Figure 8.           Rare Neurological Disease Treatment Market Impact Analysis of Drivers and Restraints

Figure 9.           Europe Rare Neurological Disease Treatment Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 10.        Europe Rare neurological disease treatment Market, By Indication 2019 & 2027 (%)

Figure 11.        Europe Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Europe Amyotrophic Lateral Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        Europe Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Europe Multiple Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Europe Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Europe Duchenne Muscular Dystrophy Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        Europe Other Indications Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        Europe Rare Neurological Disease Treatment Market, by Drug Type 2019 & 2027 (%)

Figure 19.        Europe Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        Europe Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)

Figure 22.        Europe Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24.        Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Europe Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)

Figure 26.        Europe Oral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27.        Europe Injectable Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 28.        Europe: Rare Neurological Disease Treatment Market, by Key Country – Revenue (2019) (USD Million)

Figure 29.        Europe Rare Neurological Disease Treatment Market Revenue and Forecast to 2027 (USD Million)

Figure 30.        Europe: Rare Neurological Disease Treatment Market, by Country, 2019& 2027 (%)

Figure 31.        Germany: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

Figure 32.        United Kingdom: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

Figure 33.        France: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

Figure 34.        Spain: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

Figure 35.        Italy: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        Impact of COVID-19 Pandemic In European Country Markets

 

The List of Companies - Europe Rare Neurological Disease Treatment Market

  1. Allergan plc.
  2. Bayer AG
  3. GlaxoSmithKline plc.
  4. Johnson & Johnson Services Inc.
  5. Merck & Co. Inc.
  6. Novartis AG
  7. Pfizer Inc.
  8. Sanofi
  9. Teva Pharmaceutical Industries Ltd
  10. Takeda Pharmaceutical Company Limited

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe rare neurological disease treatment market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the Europe rare neurological disease treatment market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

TIPRE00010244
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing